Spark Therapeutics Inc. (ONCE)

113.00
0.27 0.24
NASDAQ : Health Technology
Prev Close 113.27
Open 113.30
Day Low/High 112.97 / 113.40
52 Wk Low/High 34.53 / 114.20
Volume 4.04M
Avg Volume 1.65M
Exchange NASDAQ
Shares Outstanding 37.75M
Market Cap 4.29B
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spark Therapeutics (ONCE) Highlighted As Today's Perilous Reversal Stock

Spark Therapeutics (ONCE) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Strong On High Relative Volume: Spark Therapeutics (ONCE)

Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a strong on high relative volume candidate

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Analysts' Actions -- Blackstone, Chevron, Hertz, Kohl's and More

Here are Friday's top research calls, including upgrades for Chevron, Hertz and Kohl's, and a downgrade for Blackstone.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, AU, CKP, CMCT, CPLA, HURC, KSS, MTW, PH, PRTS, SAIC, UAN, ZOES Downgrades: DPLO, GNE, MRVC, VISI Initiations: ONCE Read on to get TheStreet Quant Ratings' detailed report:

Spark Therapeutics Announces Acquisition Of Genable Technologies

Spark Therapeutics Announces Acquisition Of Genable Technologies

Spark Adds New Program for One of the Leading Causes of Inherited Retinal Disease, Broadening Its Pipeline of Potential Treatments for Rare Blinding Conditions

Commit To Buy Spark Therapeutics At $20, Earn 29.3% Annualized Using Options

Commit To Buy Spark Therapeutics At $20, Earn 29.3% Annualized Using Options

Investors considering a purchase of Spark Therapeutics Inc shares, but tentative about paying the going market price of $23.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $20 strike, which has a bid at the time of this writing of $3.50.

Relative Strength Alert For Spark Therapeutics

Relative Strength Alert For Spark Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Emerald Investment Conference Shadows Groundhog Day - Investment Professionals Gathering In Philadelphia On February 3rd

Emerald Investment Conference Shadows Groundhog Day - Investment Professionals Gathering In Philadelphia On February 3rd

While the world's attention turns to Pennsylvania on February 2 nd for Groundhog Day prognostications about continuing winter weather, investment professionals will gather in Philadelphia on February 3 rd for the 2016...

WHAT'S AHEAD FOR 2016: Investment Trends And Themes To Be Highlighted At The Emerald Groundhog Day Investment Forum

WHAT'S AHEAD FOR 2016: Investment Trends And Themes To Be Highlighted At The Emerald Groundhog Day Investment Forum

Join Emerald Asset Management for the 23 rd annual Groundhog Day Investment Forum on February 3 rd in Philadelphia.

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

Feuerstein's Heroes and Zeroes of Biotech Investing in 2015

My biotech and pharma superlatives for 2015.

Spark Therapeutics Announces Filing Of Registration Statement For Proposed Public Offering

Spark Therapeutics Announces Filing Of Registration Statement For Proposed Public Offering

The Children's Hospital of Philadelphia Foundation to be a Selling Stockholder

Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting

Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting

Presentation Highlights Positive Trend in Visual Acuity, Together With Highly Statistically Significant Positive Results in Primary and First Two Secondary Efficacy Endpoints

TheStreet Quant Rating: D+ (Sell)